日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia

在慢性淋巴细胞白血病中,阿卡替尼和泽布替尼治疗期间T细胞免疫调节的时间动力学不同。

Andersson, Maria L; Lind, Olina; Heimersson, Kia; Berglöf, Anna; Del Peso Santos, Teresa; Peña-Pérez, Lucía; Wang, Qing; Mulder, Tom A; Zain, Rula; Månsson, Robert; Rosenquist, Richard; Smith, C I Edvard; Österborg, Anders; Palma, Marzia

Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment

经典霍奇金淋巴瘤患者外周血和肿瘤微环境中的免疫生物标志物与肿瘤负荷和治疗反应的关系

Mulder, Tom A; Andersson, Maria L; Peña-Pérez, Lucía; Heimersson, Kia; Xagoraris, Ioanna; Wahlin, Björn E; Månsson, Robert; Hansson, Lotta; Rassidakis, Georgios; Palma, Marzia

Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia

伊布替尼对慢性淋巴细胞白血病患者的血浆生物标志物和免疫细胞具有时间依赖性的靶向和脱靶效应

Tom A Mulder, Lucía Peña-Pérez, Anna Berglöf, Stephan Meinke, H Yesid Estupiñán, Kia Heimersson, Rula Zain, Robert Månsson, C I Edvard Smith, Marzia Palma

Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia

暂时停用伊布替尼可降低 3-4 级感染率并实现持久缓解——一项针对慢性淋巴细胞白血病患者的 1b/2 期重复用药方案研究的中期分析

Lundin, Jeanette; Mulder, Tom A; Kättström, Magdalena; Wästerlid, Tove; Uddevik, Anders; Mellstedt, Håkan; Heimersson, Kia; Hansson, Lotta; Palma, Marzia; Österborg, Anders

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers

慢性淋巴细胞白血病中的 T 细胞表现出免疫检查点和活化标志物的表达失调

Marzia Palma, Giusy Gentilcore, Kia Heimersson, Fariba Mozaffari, Barbro Näsman-Glaser, Emma Young, Richard Rosenquist, Lotta Hansson, Anders Österborg, Håkan Mellstedt